FDA approves new treatments for persistent herpes and schizophrenia; Steris to acquire Xodus Medical for $2.1 billion

The U.S. Food and Drug Administration has granted approvals for two new drugs, one targeting persistent herpes infections and another for the treatment of schizophrenia.

The herpes indication addresses infections that remain active despite standard therapy, while the schizophrenia product offers a novel option for patients with the chronic mental health disorder.

In a separate transaction, Sterilization and surgical equipment maker Steris announced it will acquire Xodus Medical, a developer of medical device reprocessing technologies, for approximately $2.1 billion.

The approvals expand therapeutic options in their respective fields, and the Steris deal underscores ongoing consolidation in the medical device sector.